MedTrace Logo

Klimadynon® in Comparison to Conjugated Oestrogens in Women Suffering From Menopausal Complaints

NCT02184364 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 161

Last updated 2014-07-14

No results posted yet for this study

Summary

To investigate, relative to placebo and conjugated oestrogens, the efficacy, safety and tolerability of a 12 weeks peroral treatment twice daily with a cimicifuga racemosa extract corresponding to 20 mg, 75 mg or 150 mg plant material on menopause-related neurovegetative and mental complaints

Conditions

Interventions

DRUG

Low dose of Klimadynon®

DRUG

Medium dose of Klimadynon®

DRUG

High dose of Klimadynon®

DRUG

Oestrofeminal®

DRUG

Placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-11-30
Primary Completion
2000-09-30

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02184364 on ClinicalTrials.gov